Publications by authors named "Corey Langer"

Claim this Profile
P
Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up of NRG Oncology RTOG 9911.
Corey J Langer, Jonathan Harris, Eric M Horwitz, Merrill Kies, Voichita Bar Ad

Int J Radiat Oncol Biol Phys· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study.
Christian Rolfo, David E Gerber, Rupesh Kotecha, Jeffrey P Ward, Wallace Akerley, Corey J Langer

Lung Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status.
Lyudmila Bazhenova, J G Hodgson, D Ross Camidge, Corey J Langer, Rudolf M Huber

Clin Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non-Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy.
Cole Friedes, Michelle Iocolano, Nikhil Yegya-Raman, John C Kucharczuk, Taine T V Pechet, Corey J Langer

Am J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study.
Alessandro Di Federico, Kaiwen Wang, Monica F Chen, Adam A Barsouk, Arianna Pagliaro, Corey J Langer

Lancet Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC.
Omar Elghawy, Adam Barsouk, Jonathan H Sussman, Benjamin A Bleiberg, Lauren Reed-Guy, Corey Langer

JTO Clin Res Rep· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and Outcomes of Brain Metastasis in Pleural Mesothelioma in the Era of Immunotherapy.
Margaret Stalker, Suzanne L Walker, Emily Lebow, Emily Ling-Lin Pai, Alex Watts, Corey J Langer

JTO Clin Res Rep· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis.
Adam Barsouk, Omar Elghawy, Alex Watts, Lauren Reed-Guy, William Tompkins, Corey J Langer

Lung Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes Following Treatment for Progression in Patients Treated With Durvalumab Consolidation in LA-NSCLC.
Margaret Stalker, Melina Marmarelis, Corey Langer, Roger B Cohen, Aditi Singh

Clin Lung Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy.
Omar Elghawy, Adam Barsouk, Lauren Reed-Guy, Margaret Stalker, Jonathan Sussman, Corey Langer

Clin Lung Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electronic Medical Record-Based Nudge Intervention to Increase Comprehensive Molecular Genotyping in Patients With Metastatic Non-Small Cell Lung Cancer: Results From a Prospective Clinical Trial.
Melina E Marmarelis, Dylan G Scholes, Tara L McWilliams, Wei-Ting Hwang, John Kosteva, Corey J Langer

JCO Oncol Pract· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Calls to action on lung cancer management and research.
May-Lucie Meyer, Fred R Hirsch, Paul A Bunn, Peter Ujhazy, David Fredrickson, Corey Langer

Oncologist· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib.
Adam Barsouk, Omar Elghawy, Alec Heidlauf, Connie Yu, Lucy Wang, Corey Langer

Lung Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive Signatures for Responses to Checkpoint Blockade in Small-Cell Lung Cancer in Second-Line Therapy Do Not Predict Responses in First-Line Patients.
Jeffrey C Thompson, Caitlin Tilsed, Christiana Davis, Aasha Gupta, Bihui Melidosian, Corey J Langer

Cancers (Basel)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era.
Michelle Iocolano, Nikhil Yegya-Raman, Cole Friedes, Xingmei Wang, Timothy Kegelman, Corey J Langer

Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLC.
David J Cantor, Christiana Davis, Christine Ciunci, Charu Aggarwal, Tracey Evans, Corey J Langer

JTO Clin Res Rep· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients.
Divij Mathew, Melina E Marmarelis, Caitlin Foley, Joshua M Bauml, Darwin Ye, Corey J Langer

Science· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation.
Adam Barsouk, Cole Friedes, Michelle Iocolano, Abigail Doucette, Roger B Cohen, Corey J Langer

Clin Lung Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Impact of Reflex Testing on Tissue-Based Molecular Genotyping in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
Melina E Marmarelis, Dylan G Scholes, Cindy M McGrath, Salvatore F Priore, Jacquelyn J Roth, Corey J Langer

Clin Lung Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors.
Cole Friedes, Michelle Iocolano, Sang Ho Lee, Bolin Li, Lian Duan, Corey J Langer

Int J Radiat Oncol Biol Phys· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression.
Cole Friedes, Nikhil Yegya-Raman, Siqi Zhang, Michelle Iocolano, Roger B Cohen, Corey J Langer

Clin Lung Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation.
Nikhil Yegya-Raman, Sang Ho Lee, Cole Friedes, Xingmei Wang, Michelle Iocolano, Corey J Langer

Radiother Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC.
Cole Friedes, Michelle Iocolano, Sang Ho Lee, Lian Duan, Bolin Li, Corey J Langer

Radiother Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sotorasib with panitumumab in chemotherapy-refractory KRAS-mutated colorectal cancer: a phase 1b trial.
Yasutoshi Kuboki, Marwan Fakih, John Strickler, Rona Yaeger, Toshiki Masuishi, Corey Langer

Nat Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Treating Fields therapy in metastatic non-small-cell lung cancer - Authors' reply.
Ticiana Leal, Corey Langer

Lancet Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis